A chemist who came up through LillyÃ¢??s labs, marketing and finally, as president and chief operating officer, Lechleiter faces major pressure.
Lilly stock has trended sideways for more than three years as investors impatiently look for news that the company can replace its top-selling Zyprexa and other major drugs as their patents expire.
With state government as a major employer as well as lots of small- and medium-sized businesses across a number of sectors, Indianapolis enjoys economic stability many cities can only dream of. But Lilly is still critical to the regionÃ¢??s prosperity.
How do you feel about LillyÃ¢??s future under Lechleiter?